ADMA Biologics Inc (ADMA)vsVertex Pharmaceuticals Inc (VRTX)
ADMA
ADMA Biologics Inc
$8.75
+0.34%
HEALTHCARE · Cap: $2.02B
VRTX
Vertex Pharmaceuticals Inc
$491.34
+2.32%
HEALTHCARE · Cap: $124.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 2296% more annual revenue ($12.22B vs $509.86M). VRTX leads profitability with a 35.5% profit margin vs 32.4%. ADMA trades at a lower P/E of 12.8x. VRTX earns a higher WallStSmart Score of 68/100 (B-).
ADMA
Hold49
out of 100
Grade: D+
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ADMA.
Margin of Safety
+48.3%
Fair Value
$949.55
Current Price
$491.34
$458.21 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 42 in profit
Keeps 32 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Attractively priced relative to earnings
15.9% revenue growth
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
Earnings declined 52.8%
Operating margin of -123.4%
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ADMA
The strongest argument for ADMA centers on Return on Equity, Profit Margin, Altman Z-Score. Profitability is solid with margins at 32.4% and operating margin at -123.4%. Revenue growth of 15.9% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : ADMA
The primary concerns for ADMA are EPS Growth, Operating Margin.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
ADMA profiles as a growth stock while VRTX is a mature play — different risk/reward profiles.
ADMA carries more volatility with a beta of 0.73 — expect wider price swings.
ADMA is growing revenue faster at 15.9% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (68/100 vs 49/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ADMA Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures and markets plasma-derived biological products specialized for the treatment of immunodeficiencies and infectious diseases in the United States. The company is headquartered in Ramsey, New Jersey.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?